Amedisys Stock Current Liabilities
| AMED Stock | USD 92.05 0.21 0.23% |
Amedisys fundamentals help investors to digest information that contributes to Amedisys' financial success or failures. It also enables traders to predict the movement of Amedisys Stock. The fundamental analysis module provides a way to measure Amedisys' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Amedisys stock.
At present, Amedisys' Non Current Liabilities Total is projected to increase significantly based on the last few years of reporting. Amedisys | Current Liabilities |
Amedisys Company Current Liabilities Analysis
Amedisys' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Amedisys Current Liabilities | 175.19 M |
Most of Amedisys' fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Amedisys is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Amedisys Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Amedisys is extremely important. It helps to project a fair market value of Amedisys Stock properly, considering its historical fundamentals such as Current Liabilities. Since Amedisys' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Amedisys' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Amedisys' interrelated accounts and indicators.
Click cells to compare fundamentals
Amedisys Current Liabilities Historical Pattern
Today, most investors in Amedisys Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Amedisys' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Amedisys current liabilities as a starting point in their analysis.
Amedisys Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Amedisys Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Amedisys has a Current Liabilities of 175.19 M. This is 90.0% lower than that of the Health Care Providers & Services sector and significantly higher than that of the Health Care industry. The current liabilities for all United States stocks is 97.78% higher than that of the company.
Amedisys Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Amedisys' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Amedisys could also be used in its relative valuation, which is a method of valuing Amedisys by comparing valuation metrics of similar companies.Amedisys is rated below average in current liabilities category among related companies.
Amedisys Fundamentals
| Return On Equity | -0.0187 | ||||
| Return On Asset | 0.0626 | ||||
| Profit Margin | (0.01) % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | 3.44 B | ||||
| Shares Outstanding | 32.68 M | ||||
| Shares Owned By Insiders | 2.26 % | ||||
| Shares Owned By Institutions | 94.90 % | ||||
| Number Of Shares Shorted | 2.39 M | ||||
| Price To Earning | 15.03 X | ||||
| Price To Book | 2.81 X | ||||
| Price To Sales | 1.34 X | ||||
| Revenue | 2.24 B | ||||
| Gross Profit | 453.98 M | ||||
| EBITDA | 216.91 M | ||||
| Net Income | (9.75 M) | ||||
| Cash And Equivalents | 17.96 M | ||||
| Cash Per Share | 0.55 X | ||||
| Total Debt | 487.21 M | ||||
| Debt To Equity | 0.53 % | ||||
| Current Ratio | 1.06 X | ||||
| Book Value Per Share | 33.30 X | ||||
| Cash Flow From Operations | 137.19 M | ||||
| Short Ratio | 8.94 X | ||||
| Earnings Per Share | (0.64) X | ||||
| Price To Earnings To Growth | 1.35 X | ||||
| Target Price | 97.78 | ||||
| Number Of Employees | 18.7 K | ||||
| Beta | 0.86 | ||||
| Market Capitalization | 3.01 B | ||||
| Total Asset | 2.06 B | ||||
| Retained Earnings | 747.92 M | ||||
| Working Capital | 23.21 M | ||||
| Current Asset | 175.26 M | ||||
| Current Liabilities | 175.19 M | ||||
| Net Asset | 2.06 B |
About Amedisys Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Amedisys's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Amedisys using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Amedisys based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Amedisys
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amedisys position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amedisys will appreciate offsetting losses from the drop in the long position's value.Moving together with Amedisys Stock
| 0.74 | ZJYL | JIN MEDICAL INTERNATIONAL | PairCorr |
Moving against Amedisys Stock
| 0.82 | GCTK | GlucoTrack | PairCorr |
| 0.63 | VKTX | Viking Therapeutics | PairCorr |
| 0.62 | DXR | Daxor | PairCorr |
| 0.62 | OMI | Owens Minor Earnings Call Next Week | PairCorr |
| 0.58 | ELYM | Eliem Therapeutics Trending | PairCorr |
The ability to find closely correlated positions to Amedisys could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amedisys when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amedisys - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amedisys to buy it.
The correlation of Amedisys is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amedisys moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amedisys moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Amedisys can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Amedisys Piotroski F Score and Amedisys Altman Z Score analysis. For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.Note that the Amedisys information on this page should be used as a complementary analysis to other Amedisys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Complementary Tools for Amedisys Stock analysis
When running Amedisys' price analysis, check to measure Amedisys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amedisys is operating at the current time. Most of Amedisys' value examination focuses on studying past and present price action to predict the probability of Amedisys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amedisys' price. Additionally, you may evaluate how the addition of Amedisys to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |
Is Amedisys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amedisys. If investors know Amedisys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amedisys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.43) | Earnings Share (0.64) | Revenue Per Share 69.004 | Quarterly Revenue Growth 0.027 | Return On Assets 0.0626 |
The market value of Amedisys is measured differently than its book value, which is the value of Amedisys that is recorded on the company's balance sheet. Investors also form their own opinion of Amedisys' value that differs from its market value or its book value, called intrinsic value, which is Amedisys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amedisys' market value can be influenced by many factors that don't directly affect Amedisys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amedisys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amedisys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amedisys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.